ConductScience.org, home

Paper4121931

Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure.

Hahn GM and 3 others. J Natl Cancer Inst, 1973. Cited by 109 papers, by iCite.

Cite this record

ConductScience Library. Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure. Papers, record 4121931. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4121931

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1973
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
109
iCite
Relative citation ratio, by iCite
5.41
iCite
Revised in PubMed
2019-05-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hahn GMG M
2Ray GRG R
3Gordon LFL F
4Kallman RFR F

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
CyclophosphamideMajor topic
FluorouracilMajor topic
Mammary Neoplasms, ExperimentalMajor topic
Animals
Bleomycin
Cell Survival
Female
Mammary Glands, Animal
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Sarcoma, Experimental
Time Factors

Source PubMed

Download CSV of topics

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.

PMIDTitleJournalYearIn PapersSource
30452663Potential lethal damage repair in glioblastoma cells irradiated with ion beams of various types and levels of linear energy transfer.J Radiat Res2019https://conductscience.org/library/papers/30452663PubMed
7000126Can dose-survival parameters be deduced from in situ assays?Br J Cancer Suppl1980https://conductscience.org/library/papers/7000126PubMed
7000122Analysis of tumour responses by excision and in vitro assay of cellular clonogenic capacity.Br J Cancer Suppl1980https://conductscience.org/library/papers/7000122PubMed
6678862In vitro cellular characteristics and survival responses of human astrocytoma clones to chloroethyl-nitrosoureas and dianhydrogalactitol.Invest New Drugs1983https://conductscience.org/library/papers/6678862PubMed
6678861Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs.Invest New Drugs1983https://conductscience.org/library/papers/6678861PubMed
6607738PLDR inhibitors: their biological and clinical implications.Br J Cancer Suppl1984https://conductscience.org/library/papers/6607738PubMed
6177286Modulation of bleomycin cytotoxicity.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6177286PubMed
6157635Effect of tumor dissaggregation on results of in vitro cell survival assay after in vivo treatment of the EMT-6 tumor: x-rays, cyclophosphamide, and bleomycin.In Vitro1980https://conductscience.org/library/papers/6157635PubMed
4131499The sensitivity of cells in exponential and stationary phases of growth to bleomycin and to 1,3-bis(2-chloroethyl)-1-nitrosourea.Br J Cancer1973https://conductscience.org/library/papers/4131499PubMed
2579666Bleomycin and misonidazole cytotoxicity.Br J Cancer1985https://conductscience.org/library/papers/2579666PubMed
2254382Adriamycin uptake and metabolism in organotypic culture of A549 human adenocarcinoma cells according to the exposure time.J Cancer Res Clin Oncol1990https://conductscience.org/library/papers/2254382PubMed
1184035Development of an in vitro colony formation assay for the evaluation of in vivo chemotherapy of a rat brain tumor.In Vitro1975https://conductscience.org/library/papers/1184035PubMed
921888Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.Br J Cancer1977https://conductscience.org/library/papers/921888PubMed
889685Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation.Br J Cancer1977https://conductscience.org/library/papers/889685PubMed
75740Studies with bleomycin and misonidazole on aerated and hypoxic cells.Br J Cancer1978https://conductscience.org/library/papers/75740PubMed
55271Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo.Br J Cancer1975https://conductscience.org/library/papers/55271PubMed
48253Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation.Proc Natl Acad Sci U S A1975https://conductscience.org/library/papers/48253PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4121931

GET https://conductscience.org/api/papers/v1/4121931/authors